Recent data has implicated MIP-1 , in multiple myeloma (MM)-associated osteolysis. However it is unclear whether the chemokine's effects are direct, to enhance osteolysis or indirect and mediated through a reduction in tumor burden, or both. It is also unclear whether MIP-1 requires other factors such as RANKL for its effects on bone. In murine 5TGM1 (Radl) myeloma-bearing mice, 
INTRODUCTION
Murine macrophage inflammatory protein-1 (MIP-1 )/CCL3 is a member of a superfamily of structurally-related and secreted low molecular weight cytokines involved in the directed migration (chemotaxis) and activation of cells which have been implicated in inflammation, wound healing, hematopoiesis, and tumorigenesis (1) (2) (3) (4) . MIP-1 was originally isolated as a macrophage product with inflammatory and chemotactic properties (5, 6) . To date, four chemokine subfamilies [CXC ( ), CC ( ), C ( ) and CX 3 C] have been described based on the position of conserved cysteine residues and MIP-1 belongs to the CC subfamily. The four classes of chemokines act on different cell types, and members of the CC subfamily including MIP-1 promote migration of monocytes/macrophages and T-lymphocytes (1, 3, 7, 8) .
Multiple myeloma (MM), the second most common adult hematological malignancy affecting 14,000 patients in the U.S. and accounting for 1-2% of cancer-related deaths (9) , is associated with severe and progressive bone destruction. The high morbidity and mortality rates associated with this plasma cell malignancy are primarily due to the effects of the unremitting osteolysis and occasional hypercalcemia (10) . There is unequivocal evidence that myeloma-induced bone loss is due to increased osteoclast activity induced by as yet unidentified locally acting factor(s) (10) . MIP-1 is expressed and secreted by myeloma cells freshly isolated from patients as well as human myeloma cell lines (11) (12) (13) (14) . Levels of MIP-1 are elevated in bone marrow plasma of myeloma patients compared with other lymphoid hematological malignancies and normal controls (11, 12) . Gene expression profiling studies also show that MIP-1 expression in mononuclear cells isolated from the bone marrow of myeloma patients is several fold higher than in those from normal subjects (14) .
MIP-1 stimulates chemotaxis of human osteoclast precursors (15) , and formation of human osteoclast-like cells in vitro (12, 15, 16) . In non-human systems, MIP-1 has also been shown to be chemotactic for cells at various stages in osteoclast ontogeny including murine granulocytemacrophage colony forming units (GM-CFU) (17) as well as isolated rat osteoclasts (18) . MIP-1 also stimulates the formation of osteoclast-like cells in rat, rabbit and porcine bone cell cultures (12, 19, 20, 21) .
Importantly, recent reports have implicated MIP-1 in the osteolysis associated with MM.
Tumor cells isolated from myeloma patients with active disease or with multiple bone lesions secreted significantly higher amounts of MIP-1 than tumor cells from patients with stable disease or patients who have none or only one radiologically-evident bone lesion (11) (12) (13) . Furthermore, neutralizing antibodies to MIP-1 partially blocked formation of osteoclast-like cells in vitro induced by freshly isolated marrow plasma from patients with myeloma or by conditioned media from human myeloma cell lines (11, 12) . However, it is still unclear how MIP-1 exerts its effects in vivo in For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From 4 myeloma, whether it affects osteoclast formation and activation directly or indirectly through a reduction in the tumor itself, or both. Moreover, there is no direct evidence that MIP-1 can induce osteoclastic bone resorption in vivo. It was reported recently that antisense inhibition of MIP-1 production blocked bone destruction in a model in which Epstein Barr virus-positive human B lymphoblastoid ARH-77 cells induce osteolysis in irradiated SCID mice (22) . Although data from this study indicate that MIP-1 is necessary for osteolysis in vivo, the question of whether MIP-1 is sufficient for tumor to form and grow in bone was not addressed.
In this manuscript, we show that MIP-1 has a dual anti-tumor and anti-osteolytic effect in myeloma in vivo in the murine 5TGM1 model of human myeloma bone disease. The 5T (Radl) series of myelomas originated spontaneously in ageing inbred C57BL mice of the KaLwRij substrain (23, 24) . Cytogenetic and molecular genetic analyses of these murine myelomas have shown that they closely resemble human myelomas (25) (26) (27) . We reported previously that when 5T33 myelomaderived 5TGM1 cells are inoculated intravenously in syngeneic or bg-nu-xid mice, they home almost exclusively to the skeleton and infrequently to the spleen (28) . Expansion within these sites results in radiographically detectable lytic bone lesions, markedly elevated serum titers of the monoclonal paraprotein and splenomegaly (29, 30) . We found that in this myeloma model, functional blockade of MIP-1 bioactivity by systemically administered neutralizing anti-MIP-1 antibodies, not only blocked osteoclastic bone destruction, but also reduced overall tumor burden and prevented splenomegaly.
In addition, intramuscular or intracardiac inoculation of Chinese hamster ovary (CHO) cells engineered to constitutively secrete human MIP-1 in mice resulted in radiographically detectable bone lesions, osteolysis and hypercalcemia, features characteristic of MM. We also show that direct injection of recombinant MIP-1 over the calvariae of mice induced a robust increase in number of osteoclasts. Together, these results strongly suggest that MIP-1 production by myeloma cells in the bone marrow microenvironment is necessary to induce skeletal pathology typical of myeloma. These data have important therapeutic implications as they strongly indicate that strategies based on functional blockade of MIP-1 bioactivity, e.g. using small molecule, synthetic antagonists of MIP-1 receptor signaling, may be efficacious in myeloma.
MATERIALS AND METHODS

Reagents
Recombinant murine and human MIP-1 , human and mouse MIP-1 ELISA kits, anti-mouse MIP (purified monoclonal rat IgG2A; clone #39624.11) and isotype control (purified rat monoclonal IgG2A; 
Construction of CHO cells expressing MIP-1
The complete sequence for human MIP-1 cDNA was amplified by RT-PCR from a pool of RNA isolated from peripheral blood lymphocytes obtained from three healthy individuals. The primers used for amplification were as follows:
MIP-1 sense primer (1) 5'-GGCAGCAGACAGTGGTCAGT-3'
MIP-1 anti-sense primer (2) 5'-TTGGTGCCATGACTGCCTAC-3'
A high fidelity DNA polymerase enzyme (Thermostable Taq- 
Cells
The 5TGM1 myeloma cell line was subcloned from a stroma-independent cell line originally established from the parent murine 5T33 (IgG2b ) myeloma (22) , and grown in long-term suspension culture (27) (28) (29) 
5TGM1 Myeloma model
Myeloma lesions were induced in bg-nu-xid mice (Balb/C; Harlan) by inoculation of 10 6 5TGM1 myeloma cells through tail veins. Thereafter, the mice were randomized into groups to receive either monoclonal rat anti-mouse MIP antibody, isotype rat IgG2a or PBS by intra-peritoneal (i.p.)
injections according to dosing schedule illustrated in Figure 1A . Sera were prepared from whole blood obtained by retro-orbital sinus bleed, under light methoxyflurane-induced anesthesia and stored frozen until mouse IgG2b was assayed using a specific ELISA (with no species crossreactivity or cross reactivity to other mouse immunoglobulins) (29) .
Mouse calvarial resorption model
The effect of recombinant human MIP-1 or murine MIP-1 on bone resorption was assessed by twice daily injections for 5 days into the subcutaneous tissue overlying parietal bones on the right side of the calvaria of normal Swiss ICR mice by use of a Hamilton syringe (33) , with a control group of mice receiving vehicle (same volume). Mice were euthanatized 4 days after the last injection, and calvariae removed and processed for histological and cytochemistry.
Experimental metastasis model
To investigate the effect of circulating MIP-1 , 
Fetal rat long bone assay
To assess bone resorption, the 45 Ca release assay was performed using fetuses from timed pregnant explanted radiolabeled long bone rudiments were incubated in the presence or absence of conditioned media harvested from cultured CHO cell clones. Culture media were replenished every 48 hours and expended media saved. At the end of the culture period, radioactivity in both media and trichloroacetic acid extracts of the bones were determined separately by liquid scintillation counting. Radioactivity in the media harvested at earlier time points was combined with that of the final conditioned media and represents total medium count. The amount of 45 Ca released (counts per minute; cpm) from individual bones over the total 5 day culture period (total medium cpm) was calculated as a percentage of total radioactivity (total medium cpm + residual bone cpm).
Radiographic analysis
High resolution whole body radiographs of ketamine-anesthesized mice were obtained with the animals immobilized in a prone position on Kodak X-Omat AR radiographic film (Eastman Kodak, Rochester, NY) using a Faxitron Cabinet X-ray unit (35 kVp for 6 sec; Faxitron X-ray Corp., Buffalo Grove, IL) (29, 34) . Radiographs were taken just before tumor inoculation and at weekly thereafter.
Analysis of number and surface area of radiolucent lesions was performed by a trained observer blinded to the composition of the different groups and treatments received.
Whole blood ionized calcium measurements
Whole blood samples were collected by retro-orbital sinus puncture into disposable heparinized capillary tubes, under light methoxyflurane-induced anesthesia, for immediate calcium measurements using a Ciba Corning 634 ISE Ca 2+ /pH analyzer.
Bone histological and cytochemical analyses
Animals were sacrificed by cervical dislocation under ketamine-induced anesthesia and skeletons removed, fixed in 10% formalin for 48 hours and decalcified in 14% EDTA. For experiments in which MIP-1 had been injected into overlying subcutaneous tissues over the calvariae, the anterior half of the frontal bones and most of the occipital bones were trimmed before embedding in paraffin with the cut edges adjacent to the lambdoid sutures at the bottom of the cassettes. With the anterior tip of the foramen magnum as a fixed starting point in each case, multiple sections (5µm thick) of the parietal bones in a posterior-anterior direction were cut. Three sections at non-consecutive levels for all calvariae were stained with hematoxylin and eosin (H & E). For each level chosen, a consecutive section was stained cytochemically for tartrate-resistant acid phosphatase (TRAP) activity, a wellrecognized marker of osteoclasts in vivo (34) . Images of the sagittal suture area between the parietal bones on the three non-consecutive H&E-stained sections and corresponding TRAP sections were digitally captured with a CoolSNAP color camera (Imaging Research, Inc.) linked to an Olympus BH-8 and quantified with the OsteoMeasure software (Osteometrics Inc., Atlanta, GA) (35) . The bone surface in each suture area was similarly traced and the suture perimeter averaged. The number of TRAP + multinucleated cells apposed to bone surfaces in each suture area was then enumerated and expressed either as osteoclasts per mm sutural bone perimeter or per mm 2 suture area.
Fixed and decalcified long bones of tumor-bearing animals, embedded in paraffin, were sectioned along the midsagittal plane at 7µm. Serial bone sections were stained with H & E and for TRAP activity, images of longitudinal sections of the tibiae and femorae were digitally captured as described above, and histomorphometric analyses performed at the proximal and distal metaphyses respectively, using OsteoMeasure (29) . The total number of TRAP + cells aligned between tumor and bone was enumerated and expressed per mm of this interface.
Statistical analysis
Data from the bone resorption assay were analyzed by one-way analysis of variance (ANOVA) with post-hoc testing using Fisher's PLSD test (StatView 5.0.1; SAS Institute Inc., Cary, NC). The significance of difference in parameters measured in all other in vivo experiments was assessed using the Mann-Whitney U test for non-parametric data (StatView).
RESULTS
Neutralization of MIP-1 bioactivity inhibits development of osteolytic lesions and slows tumor progression in myeloma-bearing mice
To test the hypothesis that MIP-1 is involved in the pathogenesis of myeloma-induced osteolysis, we investigated the effect of disrupting MIP-1 activity in vivo in the 5TGM1 myeloma model (28) (29) (30) .
Murine MIP-1 mRNA was detected in 5TGM1 cells by RT-PCR and MIP-1 protein was measurable in 5TGM1-conditioned media using a specific mouse MIP-1 ELISA (data not shown). After inoculation of 5TGM1 cells via tail veins, mice were randomized into groups and dosed for 4 weeks according to the protocol in Figure 1A . As there was no statistically significant difference in the various parameters measured (including serum paraprotein titers) between the groups that received the vehicle and the isotype IgG, data from these two control tumor-bearing groups were pooled to allow stronger statistical analyses. Twice weekly administration of anti-mouse MIP-1 antibodies significantly reduced the number of lytic lesions and myeloma tumor burden in bones (determined on H& E-stained sections) compared to controls ( Figure 1B ). Not only were there fewer osteolytic lesions in tumor-bearing mice that received the anti-mouse MIP-1 antibodies, the lesions were also significantly smaller with a 50% reduction in the mean surface area, compared to controls (data not 
DISCUSSION
At present, it is unclear how MIP-1 , influences osteoclastic bone resorption in myeloma. MIP-1 is produced excessively by freshly isolated malignant plasma cells from patients and human myeloma cell lines (11) (12) (13) , and is present in the bone marrow and marrow supernatants of myeloma patients with bone disease at much higher levels compared to patients no bone disease and those with other hematological malignancies and normal controls (11) (12) (13) (14) . It was surmised that the chemokine may play a role as a mediator in the bone disease associated with myeloma (11-13), since MIP-1 stimulates not only chemotaxis of monocyte-macrophage lineage cells (including osteoclast precursors and mature osteoclasts) (15, 17, 18) , but also osteoclastic differentiation and resorption in vitro (15, 19, 20, 21) . Here we show that functional blockade of MIP-1 bioactivity with neutralizing anti-MIP-1 antibodies attenuates tumor-induced lytic bone lesions in murine 5TGM1 myelomabearing mice consistent with the notion that the chemokine plays an important role in the osteolysis associated with myeloma in vivo. Surprisingly, we also found a concomitant decrease in overall tumor burden suggesting a previously unrecognized effect of MIP-1 on myeloma tumor progression.
We also demonstrate in a variety of experimental model systems, the osteoclastogenic nature of
MIP-1 when expressed adjacent to bone surfaces in vivo.
An unexpected finding in our study was the increased incidence and size of radiologically identifiable lytic lesions, which was confirmed histologically, in long bones of contralateral hind limbs of mice bearing intramuscular human MIP-1 -expressing CHO tumors. In addition, the osteolytic lesions developed at a much faster rate in CHO/MIP-1 tumor-bearing mice compared to CHOEV tumor-bearing mice. Mock-or empty vector-transfected CHO cells possess the capacity to metastasize to bone when inoculated into left ventricles of mice (38) . However, previous studies by our group have shown that when CHO cells are inoculated intramuscularly or subcutaneously, only a small number of these cells leave the primary tumor site and metastasize to other tissues (39) (40) (41) (42) . In these settings, metastatic bone lesions are uncommon presumably because a significant proportion of the migrating cells arrest in the pulmonary bed. Since naïve CHO cells cannot respond to MIP-1 and need to be transfected with either CCR1 or CCR5 for intracellular calcium signaling to be To clarify this, we performed in vivo experiments injecting MIP-1 over the calvariae of RANK (-/-) mice. In contrast to its marked osteoclastogenic effect in normal mice, MIP-1 had no effect in RANK (-/-) mice strongly suggesting that an intact RANK signaling pathway is required for the in vivo It was recently reported that inhibiting MIP-1 production using an anti-sense approach also Multiple myeloma cannot be cured by standard chemotherapeutic approaches and the high morbidity and mortality associated with this malignancy are mainly due to complications of osteoclast-mediated bone destruction (10) . Although much progress has been made recently in the therapeutic use of N-BPs for cancer-induced osteolysis, this has not resulted in significantly improved clinical outcomes in myeloma patients. Understanding the pathophysiology of myeloma progression and associated bone destruction is key to identification of new interventions that may concomitantly impact tumor burden and reduce further bone loss thereby improving the quality of life of patients.
In summary, the data presented in this report strongly suggest that MIP-1 impacts both osteoclasts and tumor cells in myeloma. We surmise that production of MIP-1 in the bone milieu is necessary to induce myelomatous lesions, and that further investigation of the anti-tumor and antiosteolytic efficacy of MIP-1 receptor antagonists in valid preclinical models of myeloma would thus be worthwhile. Potent and orally-bioavailable, synthetic small molecule antagonists of both CCR1 and CCR5 are already available, under development for other disease conditions (56, 57 Representative sections of calvariae from three separate mice are shown (each of the top three panels on either side represents mid-sagittal suture area of calvaria of one mouse; bottom panel on either side represents region of calvariae away from the midline).
(B) Although injection of MIP-1 induced osteoclast formation and bone resorption in calvariae of wild type littermates (arrows), it had no effect in RANK null mutant mice. Note lack of marrow spaces and bowing of calvariae of RANK (-/-) mice due to absence of osteoclasts.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From
